Tag Archives: GILD

stock market information

Corrections & Clarifications: Corrects the spelling of Pippin Mader’s name and title

Just weeks after President Trump signaled he’s ready to roll back tough federal vehicle fuel standards, California’s clean-air authority on Friday affirmed that it won’t budge on its own tough standards.

The California Air Resources Board on Friday reaffirmed its own set of regulatory standards for the automotive industry, setting it and 12 other mostly East and West Coast states that are likely to follow its lead on a different path than the rest of the nation.

The 16-member board of California regulators voted unanimously to reaffirm its existing standards for model years 2022 to 2025 for zero emission vehicle sales and greenhouse gas emissions in California despite pleas from the industry for changes.

stock market information: Quality Systems, Inc.(QSII)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Tuesday, our Elite Opportunity Pronewsletter suggested small cap health care technology stock Quality Systems, Inc (NASDAQ: QSII) as a short-term trading opportunity after popping sharply on news:

stock market information: Sinovac Biotech Ltd.(SVA)

Advisors’ Opinion:

  • [By Monica Gerson]

    Sinovac Biotech Ltd. (NASDAQ: SVA) is expected to post its quarterly earnings.

    Supercom Ltd (NASDAQ: SPCB) is estimated to post its quarterly earnings at $0.15 per share on revenue of $9.03 million.

stock market information: Intrexon Corporation(XON)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Intrexon (XON) has made a small yet strategic acquisition in buying GenVec (GNVC); with the purchase, XON gets AdenoVerse, a platform of adenovirus vectors for delivering drugs and vaccines that dovetails nicely with its existing suite of gene therapy technologies, suggests John McCamant, editor of The Medical Technology Stock Letter.

stock market information: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Laurie Kulikowski]

    As GILD continues to look for further growth drivers beyond HIV and HCV, investor focus unsurprisingly centers on future BD (optionality remains strong with $25B in cash at 3Q15). In the meantime, HCV has turned into a mammoth cash cow allowing GILD to generate ~$15.5B in FCF over the first 9 months of 2015. With ~$11B remaining in its current share repo plan paired with a $0.43/share dividend, we expect GILD to continue returning cash to shareholders. 

  • [By Jack Foley]

    Up to now, I have been very vocal with respect to my bullish opinion regarding Gilead Sciences (NSDQ:GILD). Many investors and analysts alike have been trying to pick a bottom in the stock this year, but the stock stubbornly continues to trade below $75 a share. Worrying downward trends with respect to the company’s HCVdivision remain the dominant theme among investors. Gilead’s HCV division slipped by a whopping 31% last quarter, which resulted in HCV sales of $3.3 billion, which was well below expectation. The stock is now down almost 40% from its high back in June 2015. At present, investors simply can’t see a swift turnaround in the company’s quarterly sales. This has resulted in the company now trading with a price-to-earnings ratio of 6.94 which is ludicrously cheap for a company with a market cap of around $100billion. Nevertheless, the question still remains whether the stock is going lower.

  • [By Cory Renauer]

    Get your popcorn and settle in for a biotechnology Clash of the Titans. In one corner stands Celgene Corporation (NASDAQ:CELG), an oncology powerhouse on the rise. In the other corner stands Gilead Sciences, Inc. (NASDAQ:GILD), an antiviral heavyweight that may be past its prime.

  • [By Spencer Israel]

    And these were the most popular sells:

    Bristol-Myers Squibb Co(NYSE: BMY)
    Pfizer Inc. (NYSE: PFE)
    Gilead Sciences, Inc. (NASDAQ: GILD)
    ConocoPhillips (NYSE: COP)
    Chevron Corporation (NYSE: CVX)
    The following chart shows the IMX performance since it's inception at the end of 2012. You can see how it's generally correlated to the broader equities market. 

  • [By Keith Speights]

    When John Milligan speaks, people listen — especially if they’re Gilead Sciences (NASDAQ:GILD) shareholders.

    The big biotech’s CEO and its CFO Robin Washington sat down to field questions at the RBC Capital Markets 2017 Healthcare Conference in New York City on Wednesday. Milligan spoke directly to some of the most pressing concerns for Gilead shareholders. Here are three things he said that you’ll definitely want to know.

stock market information: Federal-Mogul Holdings Corporation(FDML)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Mario Gabelli on Monday gained the upper hand in his battle to force Carl Icahn to sweeten his offer for a car-parts manufacturer. Icahn, who owns 82 percent of Federal-Mogul (NASDAQ: FDML), offered $9.25 a share for the remaining stake but fell way short after Gamco Investors boss Gabelli — who has a leading stake in Federal-Mogul — pressed for a higher price.

stock market information: Occidental Petroleum Corporation(OXY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Stocks that made the cut include General Motors (GM), Coca-Cola Company (KO), Occidental Petroleum (OXY), JPMorgan Chase (JPM), and General Electric (GE).

  • [By Lee Jackson]

    These companies also reported insider buying last week: Carrizo Oil and Gas Inc. (NASDAQ: CRZO), Medifast Inc. (NYSE: MED), Medley Capital Corp. (NYSE: MCC), Occidental Petroleum Corp. (NYSE: OXY) and Sothebys (NYSE: BID).

  • [By Garrett Cook]

    Citi notes that presentations from producers (the bank specifically notes Anadarko (NYSE: APC), Occidental Petroleum (NYSE: OXY), and Pioneer Natural Resources (NYSE: PXD)) showed a lack of commitment to enter 2017 hedge programs to lock in the economics for drilling.

  • [By Paul Ausick]

    Occidental Petroleum Corp. (NYSE: OXY) dropped about 1.6% Friday, to post a new 52-week low of $64.19 after closing at $65.25 on Thursday. The stock’s 52-week high is $78.48. Volume was about 15% below the daily average of around 4.7 million shares. The company had no specific news.

  • [By Chris Lange]

    Occidental Petroleum Corp.s (NYSE: OXY) short interest increased to 16.11 million shares from the previous reading of 15.70 million. Shares were recently at $62.83, in a 52-week range of $61.01 to $78.48.

  • [By Ben Levisohn]

    We have seen several dividend cuts in the recent past, including Anadarko Petroleum cutting its dividend by 81%…and we expect more companies to follow suit. Chesapeake Energy (CHK), ConocoPhillips (COP), Encana,Marathon Oil and Noble Energy (NBL) are among energy companies that have also cut dividends in the past 12 months, but dividend requirements even after several cuts will consume ~26% of 2016 estimated cash flow at current dividend rates (15% excluding Occidental Petroleum (OXY)) for the large cap E&Ps we cover. We believe most of the companies with a dividend yield of more than 1.5% should consider cutting the dividend and find the following companies more likely than not to reduce dividends:Apache (2.5% yield),Devon Energy (4%),Encana (1.5%) andMarathon Oil (2.5%). We believe Canadian Natural Resource (CNQ) (3.0%) is likely to maintain its dividend while Occidental (4.5%) has the financial strength to maintain or even increase the dividend…

top stocks to invest in today

Last October, we issued a trading call to buy Bank of America Corp. (NYSE: BAC) on the drop to $15. This was shortly before the stock rallied to its 52-week high at $25.50, which generated gains of over 61%. Over the past few weeks, we have seen the market give back some of those gains, and we have received messages from readers asking whether it still makes sense to be holding these positions. Categorically, the answer is still a clear “yes,” as the recent declines have been driven by external events that have done almost nothing to alter the fundamental strength of the company. Further, these declines should be viewed as another buying opportunity to gain exposure in a solid company that stands to benefit greatly from the next round of rate hikes that are expected at the Federal Reserve.

top stocks to invest in today: (VIAB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By WWW.THESTREET.COM]

    To be sure, there are differences between all these new offerings both on price and channel selection, as well as functions for binge-watching and recording live shows. Google’s YouTube TV won’t include networks owned by Time Warner, Viacom (VIAB) and AMC Networks (AMCX) , but it will offer a DVR service that saves programs for nine months. Play Station Vue offers lots of digital video games, which plays into a large part of Sony’s business.

  • [By Paul Ausick]

    Viacom Inc. (NASDAQ: VIAB) posted a new 52-week low of $27.22 on Tuesday, down about 4.6% from Friday’s closing price of $28.52. The stock’s 52-week high is $46.72. Volume totaled around 5.8 million shares, about 15% above the daily average. The company had no specific news.

  • [By Keith Noonan]

    While 2016 played host to a range of films that underperformed, the biggest flops belonged to Disney (NYSE:DIS), Viacom (NASDAQ:VIA) (NASDAQ:VIAB) and Lions Gate Entertainment (NYSE:LGF.A). Click through the presentation below to get the details on the year’s five biggest film flops and to learn what last year’s movie misfires mean for the companies involved.

top stocks to invest in today: Cidara Therapeutics, Inc.(CDTX)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

top stocks to invest in today: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Chris Lange]

    Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday. The company posted $2.70 in earnings per share (EPS) and $7.3 billion in revenue, compared with the consensus estimates from Thomson Reuters that called for $2.61 in EPS and $7.15 billion in revenue. The same period from last year had $3.32 in EPS and $8.51 billion in revenue.

  • [By Cory Renauer]

    Like most of you, I don’t like to lose money. So you might be wondering why I was so quick to scoop up more shares of Gilead Sciences (NASDAQ:GILD) stock after its latest earnings report. After all, management shared a forecast for 2017 hepatitis C antiviral sales 39% lower than 2016 figures, and that’s at the high end of the provided range.

  • [By Kumar Abhishek]

    The election of Donald Trump as next US President has brought in some good news for Gilead stock. Firstly, the likelihood of action against the company for “price gouging” has declined heavily. Also, Mr. Trump’sproposal to tax repatriation of cash from overseas to U.S. at a concessional rate of 10% instead of 25% can save billions of dollars for the company, if it chooses to repatriate the cash. Gilead has more that $15 billion in overseas cash. Mr. Trump’s proposal could save it around $2.2 billion in taxes. Mr. Trump’s proposal to lower corporate taxes may not have much impact on Gilead as its current tax rate is very low at 17%. (Also Read: The Rally In Gilead Sciences Inc (GILD) Stock Is Just Getting Started)

  • [By Laurie Kulikowski]

    The revenue growth came in higher than the industry average of 13.4%. Since the same quarter one year prior, revenues rose by 37.3%. Growth in the company’s revenue appears to have helped boost the earnings per share.

    The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 68.4% when compared to the same quarter one year prior, rising from $2,731.27 million to $4,600.00 million.

     

  • [By Kumar Abhishek]

    Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in a massive underperformance. Gilead stock has underperformedeven the iShares NASDAQ Biotech Index ETF (NASDAQ:IBB) which has returned more than 14% during the same period. Gilead stock has been making lower lows and lower highs going into the earnings, indicating a clear downtrend in the stock. The stock hit its 52 week low of $69.78 recently on January 24th, just days ahead of its Q4 earnings result. Gilead Sciences, Incis scheduled to report its Q4 2016 and FY 2016 earnings on 7th of February, after the market close.

top stocks to invest in today: Tata Motors Ltd(TTM)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    I’ve been watching Tata Motors Ltd. (TTM) over the past few years with increasing interest. As India’s largest carmaker, it stands to benefit from the tenfold projected growth in the middle class in both India and China over the next decade.

Top Performing Stocks To Buy For 2018

As the market closes out the final week of an eventful year, fund managers have one last chance to modify their holdings ahead of year-end investor updates. Sometimes, these fund managers try to paint a slightly rosier picture of their annual performance by tweaking their holdings just prior to the year’s end. The practice of buying top performers and dumping laggards in the final days of the year is known as window dressing.

Why Window Dress?

According to Schaeffer’s Investment Research, window dressing can create tradeable opportunities in some of the best- and worst-performing stocks in the market at the end of the year.

Top Performing Stocks To Buy For 2018: Synta Pharmaceuticals Corp.(SNTA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Synta Pharmaceuticals Corp. (NASDAQ: SNTA) shares were also up, gaining 61 percent to $0.393. Synta Pharmaceuticals announced plans to merge with privately-held Madrigal Pharmaceuticals.

Top Performing Stocks To Buy For 2018: Roche Holding AG (RHHBY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Only Roche (OTCQX:RHHBY) is producing a drug with a similar mechanism to Gilead’s GS-9620. Other drug manufacturers are focused on a variety of methods which could be supportive when used in combination with GS-9620. More information on the drug is expected to be released from Phase 2 clinical trial results in Q1’17. It’s important to note from AASLD abstracts (Abstract 1851) and earlier clinical trial results (page 11) that there is not much evidence of efficacy at this point in time.

  • [By WWW.KIPLINGER.COM]

    EFAV is another low-volatility product, this one centered around the MSCI EAFE Index, an ex-U.S./Canada index that includes companies in developed markets across Europe, Australasia and the Far East. EFAV uses Barras multi-factor risk model to weed out the riskiest MSCI EAFE Index stocks, resulting in a current 230-stock low-vol portfolio stuffed with stable blue chips. Stocks like multinational foods giant Nestle SA (NSRGY) and healthcare giant Roche Holding Ltd. (RHHBY) line EFAVs top holdings, and help throw off a decent yield of about 2.5%.

  • [By Brian Orelli]

    Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed “Aphinity.”

  • [By SEEKINGALPHA.COM]

    Source: Biogen’ Q2 2017 Results Presentation

    Tysabri sales were $496, in line with consensus. This dynamic has been helpful to reassure investors that the impact from the recent launch of Roches (OTCQX:RHHBY) Ocrevus has been limited and that the franchise could be still defended over the next 5 years.

  • [By SEEKINGALPHA.COM]

    As with INCY, the focus of Regeneron (NASDAQ:REGN) is cutting-edge science to produce superior molecules that have limited competition. Its flagship drug Eylea took on and defeated the incumbent, Lucentis from Roche (OTCQX:RHHBY), by having both a longer activity leading to less frequent injections into the eye and an additional mechanism of action. This provides it partial insulation from pricing pressures; and, REGN has never taken a price increase on Eylea, which has been on the market since late 2011. Eylea is now selling $5 B globally, a number that is rising and that I believe exceeds the pace set by Revlimid and almost every other drug in history (inflation not accounted for, though).

  • [By Keith Speights]

    Eisai (NASDAQOTH:ESALY), Novo Nordisk (NYSE:NVO), and Roche Holding Ltd. (NASDAQOTH:RHHBY) fit that description well. Each of these companies markets obesity drugs, but each also sells a broad array of other products with multiple pipeline candidates potentially on the way. Here’s why Eisai, Novo Nordisk, and Roche rank as the three best obesity-drug stocks to buy in 2017.

Top Performing Stocks To Buy For 2018: AmerisourceBergen Corporation (Holding Co)(ABC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    AmerisourceBergen (ABC) sprinted to the top of the S&P 500 after releasing Street-beating earnings this morning.

    Getty Images

    Shares of AmerisourceBergen jumped 8.8% to $$75.96 today, while the S&P 500 dropped fell 0.7% to 2,097.94.

    Leerink’s David Larsen and Matt Dellelo traces today’s big gain to Amerisource’s big drop following McKesson’s (MCK) earnings last week:

    This morningAmerisourceBergen reported adjusted EPS of $1.30, which was well ahead of Leerink/consensus of $1.22/$1.22. The quality of the beat appears decent, with some pressure in gross margin, completely offset by lower SG&A costs. Given the dramatic reduction in guidance provided byMcKesson (MP), investors had been very cautious heading into the quarter. We are pleased to see that F2017 EPS guidance of $5.63-$5.88 brackets Leerink/consensus estimates of $5.85/$5.82. Brand inflation is now expected to be in the +7-9% range from 10% previously, and F2017 is expected to be back-half loaded. Our first impression of the quarter is that the print and guide are good and there will likely be a relief rally in the shares.

    AmerisourceBergen’s market capitalization rose to $18.1 billion from $16.6 billion yesterday.

Top Performing Stocks To Buy For 2018: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Laurie Kulikowski]

    We rate GILEAD SCIENCES INC as a Buy with a ratings score of A. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. 

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .

  • [By Laurie Kulikowski]

    As GILD continues to look for further growth drivers beyond HIV and HCV, investor focus unsurprisingly centers on future BD (optionality remains strong with $25B in cash at 3Q15). In the meantime, HCV has turned into a mammoth cash cow allowing GILD to generate ~$15.5B in FCF over the first 9 months of 2015. With ~$11B remaining in its current share repo plan paired with a $0.43/share dividend, we expect GILD to continue returning cash to shareholders. 

  • [By Kumar Abhishek]

    The election of Donald Trump as next US President has brought in some good news for Gilead stock. Firstly, the likelihood of action against the company for “price gouging” has declined heavily. Also, Mr. Trump’sproposal to tax repatriation of cash from overseas to U.S. at a concessional rate of 10% instead of 25% can save billions of dollars for the company, if it chooses to repatriate the cash. Gilead has more that $15 billion in overseas cash. Mr. Trump’s proposal could save it around $2.2 billion in taxes. Mr. Trump’s proposal to lower corporate taxes may not have much impact on Gilead as its current tax rate is very low at 17%. (Also Read: The Rally In Gilead Sciences Inc (GILD) Stock Is Just Getting Started)

  • [By Sean Williams]

    Though drugmaker Gilead Sciences (NASDAQ:GILD) has lost 25% over the trailing-12-month period, underperforming the S&P 500 by 41 percentage points, I believe now would be the perfect time for income investors to give it a closer look.

candlestick chart

Shares are down about 10% on Thursday after Twitter’s (NYSE:TWTR) as investors digest the company’s slowing revenue and user growth reported in its fourth quarter. But there were a few bright spots in the company’s earnings release as well. Here’s an overview of Twitter’s fourth-quarter performance.

The raw numbers

Metric

Q4 2016

Q4 2015

Change

Revenue

$717.2 million

$710.5 million

1%

Net loss per share

($0.23)

($0.13)

($0.10)

Non-GAAP net earnings per share

$0.16

candlestick chart: Power Solutions International, Inc.(PSIX)

Advisors’ Opinion:

  • [By Brent Slava]

    Power Solutions International Inc (NASDAQ: PSIX) shares plunged as much as 30 percent Tuesday on a report the company would be delisting from Nasdaq Inc (NASDAQ: NDAQ).

candlestick chart: Gentex Corporation(GNTX)

Advisors’ Opinion:

  • [By Lisa Levin] Related TRST Earnings Scheduled For October 21, 2016 Major Accounting Changes Are Coming To The Financial Industry
    Related MORN One Of The World's Most Powerful Women, Fidelity Personal Investing President Kathleen Murphy, To Tell Her Story At The Benzinga Global Fintech Awards The 2017 Benzinga Global Fintech Awards Will Include An 'Unprecedented Group' Of Judges Morningstar Packs Conference Lineup For Financial Advisors (Investor’s Business Daily) Companies Reporting Before The Bell
    Rockwell Collins, Inc. (NYSE: COL) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.33 billion.
    General Electric Company (NYSE: GE) is expected to report quarterly earnings at $0.17 per share on revenue of $26.46 billion.
    Honeywell International Inc. (NYSE: HON) is estimated to report quarterly earnings at $1.60 per share on revenue of $9.32 billion.
    Interpublic Group of Companies Inc (NYSE: IPG) is expected to report quarterly earnings at $0.03 per share on revenue of $1.76 billion.
    Schlumberger Limited. (NYSE: SLB) is estimated to report quarterly earnings at $0.26 per share on revenue of $7.02 billion.
    SunTrust Banks, Inc. (NYSE: STI) is expected to report quarterly earnings at $0.83 per share on revenue of $2.21 billion.
    ManpowerGroup Inc. (NYSE: MAN) is projected to report quarterly earnings at $1.11 per share on revenue of $4.68 billion.
    Kansas City Southern (NYSE: KSU) is estimated to report quarterly earnings at $1.15 per share on revenue of $593.82 million.
    Stanley Black & Decker, Inc. (NYSE: SWK) is projected to report quarterly earnings at $1.19 per share on revenue of $2.74 billion.
    WABCO Holdings Inc. (NYSE: WBC) is estimated to report quarterly earnings at $1.44 per share on revenue of $721.89 million.

candlestick chart: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Jack Foley]

    Up to now, I have been very vocal with respect to my bullish opinion regarding Gilead Sciences (NSDQ:GILD). Many investors and analysts alike have been trying to pick a bottom in the stock this year, but the stock stubbornly continues to trade below $75 a share. Worrying downward trends with respect to the company’s HCVdivision remain the dominant theme among investors. Gilead’s HCV division slipped by a whopping 31% last quarter, which resulted in HCV sales of $3.3 billion, which was well below expectation. The stock is now down almost 40% from its high back in June 2015. At present, investors simply can’t see a swift turnaround in the company’s quarterly sales. This has resulted in the company now trading with a price-to-earnings ratio of 6.94 which is ludicrously cheap for a company with a market cap of around $100billion. Nevertheless, the question still remains whether the stock is going lower.

  • [By Ben Levisohn]

    Shares of Gilead Sciences (GILD) have been under pressure ever since investors realized its hepatitis-C sales weren’t going to be able to keep growing. Since then, the market has been looking for Gilead to make an acquisition to kick start its growth again, while writing off its pipeline. Is that a mistake? It could be according to Jefferies analyst Brian Abrahams and team.

    Pixabay

    What are they seeing that others are missing? They explain:

    Based on an EASL title posted in recent weeks but we believe not broadly discussed, ACC inhibitor GS-0976 – one of GILD’s least-talked-about assets in NASH, in our opinion – appears to have demonstrated significant positive effects in the as-yet-unreported ph.II NASH study. The presentation title, “Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to suppression of hepatic de novo lipogenesis and significant improvements in MRI-PDFF, MRE, and markers of fibrosis after 12 weeks of therapy in patients with NASH,” indicates to us that recently-acquired ’0976′s novel mechanism, which has good scientific rationale, may likely be playing out…

    We believe this meaningfully de-risks a second NASH asset, and given add’l catalysts over the next 12mo could set the stage for increased recognition of potentially meaningful drivers w/in GILD’s internal pipeline. We see upside potential.

    I threw in the towel on Gilead in a column on Gilead earlier this month, when I argued that even an acquisition would not be enough to get it growing again.

    Shares of Gilead Sciences have dipped 0.1% to $68.97 at 1:05 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has risen 0.4% to $296.51.

     

     

  • [By Keith Speights]

    There are several choices for investing in HIV drug stocks. Three of the best options for long-term investors are Gilead Sciences (NASDAQ:GILD), GlaxoSmithKline (NYSE:GSK), and Merck (NYSE:MRK). Here’s why these HIV drug stocks could be solid picks in 2017.

candlestick chart: FIRST REPUBLIC BANK(FRC)

Advisors’ Opinion:

  • [By Lisa Levin] Related WFC Why Bank ETFs Fell On Friday Despite Decent Earnings Phil's Stock World: Funtime Friday Earnings Season Starts Today Rising Book Values and Margins of Safety (GuruFocus)
    Related C Earnings Preview: Financial Giants BAC, GS, And MS Report Q2 Results This Week Why Bank ETFs Fell On Friday Despite Decent Earnings Palo Capital, Inc. Buys Citigroup Inc, Schlumberger, NetApp Inc, Sells Citrix Systems Inc, … (GuruFocus) Companies Reporting Before The Bell
    Wells Fargo & Co (NYSE: WFC) is estimated to report quarterly earnings at $1.02 per share on revenue of $22.51 billion.
    Citigroup Inc (NYSE: C) is projected to report quarterly earnings at $1.26 per share on revenue of $17.71 billion.
    JPMorgan Chase & Co. (NYSE: JPM) is expected to report quarterly earnings at $1.65 per share on revenue of $25.61 billion.
    PNC Financial Services Group Inc (NYSE: PNC) is projected to report quarterly earnings at $2.02 per share on revenue of $4.00 billion.
    First Republic Bank (NYSE: FRC) is estimated to report quarterly earnings at $1.1 per share on revenue of $675.70 million.
    First Horizon National Corp (NYSE: FHN) is projected to report quarterly earnings at $0.28 per share on revenue of $337.89 million.

     

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Citigroup Inc (NYSE: C) to report quarterly earnings at $1.26 per share on revenue of $17.71 billion before the opening bell. Citigroup shares rose 0.30 percent to $67.22 in after-hours trading.
    Analysts are expecting JPMorgan Chase & Co. (NYSE: JPM) to have earned $1.65 per share on revenue of $25.61 billion in the latest quarter. JPMorgan will release earnings before the markets open. JPMorgan shares gained 0.48 percent to $93.55 in after-hours trading.
    Cyberark Software Ltd (NASDAQ: CYBR) lowered its guidance for the second quarter. The company now expects total revenue of $57.0 million to $57.5 million, versus earlier guidance of $61.0 million to $62.0 million. Cyberark shares dipped 17.65 percent to $42.00 in the after-hours trading session.
    Before the opening bell, First Republic Bank (NYSE: FRC) is projected to report quarterly earnings at $1.1 per share on revenue of $675.70 million. First Republic Bank shares dropped 0.80 percent to close at $101.35 on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

candlestick chart: Coca-Cola Enterprises, Inc.(CCE)

Advisors’ Opinion:

  • [By Lisa Levin] Related LOV Match Group And Spark Networks: A Valentine's Day Case Study 20 Biggest Mid-Day Losers For Thursday
    Related VKTX 15 Biggest Mid-Day Losers For Tuesday 18 Biggest Mid-Day Losers For Wednesday Companies Reporting Before The Bell
    Canadian Solar Inc. (NASDAQ: CSIQ) is expected to report its quarterly earnings at $0.32 per share on revenue of $690.27 million.
    General Mills, Inc. (NYSE: GIS) is projected to report its quarterly earnings at $0.71 per share on revenue of $3.84 billion.
    Coca-Cola European Partners Plc (NYSE: CCE) is estimated to report its quarterly earnings at $0.45 per share on revenue of $2.72 billion.
    Lands' End, Inc. (NASDAQ: LE) is expected to report its quarterly earnings at $0.35 per share on revenue of $459.43 million.
    Francesca's Holdings Corp (NASDAQ: FRAN) is estimated to report its quarterly earnings at $0.37 per share on revenue of $145.91 million.
    Cheetah Mobile Inc (ADR) (NYSE: CMCM) is projected to report its quarterly earnings at $0.06 per share on revenue of $178.04 million.
    Neogen Corporation (NASDAQ: NEOG) is estimated to report its quarterly earnings at $0.27 per share on revenue of $90.05 million.
    Lennar Corporation (NYSE: LEN) is projected to post earnings for its first quarter.
    Fifth Street Asset Management Inc (NASDAQ: FSAM) is expected to report its quarterly earnings at $0.14 per share on revenue of $25.12 million.

     

candlestick chart: Unilever N.V. (UNLVF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    In sum, the three companies are equally valued at generous multiples. It is difficult to choose one of them based on fundamentals or valuations, but we like the strategy of Nestl茅 and P&G more than Unilever. Therefore, we recommend investing in these companies only if someone is interested in a limited but relatively safe upside potential. Good entry prices would be as follows: Nestl茅 (OTCPK:NSRGF) at CHF 70.1 or $70.1 for the ADR , P&G at $83.6 and Unilever (OTC:UNLVF) at 34.1 or $38 for the ADR (NYSE:UN).